<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593944</url>
  </required_header>
  <id_info>
    <org_study_id>MDX1342-02</org_study_id>
    <secondary_id>IM130-002</secondary_id>
    <nct_id>NCT00593944</nct_id>
  </id_info>
  <brief_title>Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <acronym>MDX1342-02</acronym>
  <official_title>A Phase 1, Open-Label, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients With CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see at what dose MDX-1342, a monoclonal antibody, is safe and
      tolerable for patients with chronic lymphocytic leukemia (CLL). Information on any responses
      that patients may have to the drug will also be collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lymphocytic leukemia (CLL) is a monoclonal hematopoietic disorder characterized by a
      progressive expansions of lymphocytes of B-cell lineage. These small, mature-appearing
      lymphocytes accumulate in the blood, bone marrow, lymph nodes, and spleen. CLL is a common
      leukemia in the wester world and accounts for 25% to 30% of adult leukemias. CD19,an integral
      membrane protein, is expressed by pro-B cells and functions as a co-stimulatory molecule that
      regulates mature B-cell activation and enhances B-cell proliferation. MDX-1342, a fully human
      monoclonal antibody, has demonstrated to specifically bind to human CD19 antigen with high
      affinity. Therefore, it is theorized that MDX-1342 will block activation of B cell
      stimulation, decreasing the number of cancerous B cell clones.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence and severity of treatment-emergent adverse events</measure>
    <time_frame>all events will be followed to resolution</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical laboratory tests</measure>
    <time_frame>study duratation - each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination</measure>
    <time_frame>study duration - each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiogram</measure>
    <time_frame>at screening and study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diagnostic testing</measure>
    <time_frame>at screening and study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics sampling</measure>
    <time_frame>at each dosing visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive active MDX-1342.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDX-1342</intervention_name>
    <description>MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  relapsed/refractory CD19-positive CLL

          -  At least 28 days since prior treatment for CLL

          -  ECOG PS 0-2

          -  Screening laboratory values must be met

        Exclusion Criteria:

          -  No prior anti-CD19 antibody tx

          -  No active, uncontrolled infection

          -  No prior allogeneic bone marrow transplant

          -  No autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>May 21, 2013</last_update_submitted>
  <last_update_submitted_qc>May 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>B cell</keyword>
  <keyword>leukemia</keyword>
  <keyword>lymphocyte</keyword>
  <keyword>antibody</keyword>
  <keyword>monoclonal</keyword>
  <keyword>cancer</keyword>
  <keyword>blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

